The PD-1/PD-L1 inhibitors market is predicted to be valued at US$ 49.5 billion in 2023, rising to US$ 123.3 billion by 2033. Throughout the forecast period, the market is expected to grow at a substantial CAGR of 9.6%. The usage of PD-1 and PD-L1 inhibitors, which are significant immune checkpoint inhibitors used as front-line treatments for a …
Continue reading “PD-1/PD-L1 Inhibitors Market is projected to surpass US$ 123.3 billion by 2033”